Stockscreener 앱 받기
9.78
2.73%
0.26
전일 마감가:
$9.52
열려 있는:
$9.77
하루 거래량:
414.32K
Relative Volume:
0.94
시가총액:
$1.34B
수익:
$53.99M
순이익/손실:
$-222.30M
주가수익비율:
-5.3837
EPS:
-1.8166
순현금흐름:
$-213.50M
1주 성능:
+7.95%
1개월 성능:
-7.91%
6개월 성능:
+2.19%
1년 성능:
+67.18%
1일 변동 폭
$9.62
$9.98
1주일 범위
$9.00
$9.98
52주 변동 폭
$5.05
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
9.78 | 1.34B | 53.99M | -222.30M | -213.50M | -1.8166 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-05-28 | 개시 | Deutsche Bank | Buy |
| 2024-10-07 | 개시 | Piper Sandler | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2020-11-20 | 개시 | BofA Securities | Buy |
| 2020-09-22 | 개시 | Goldman | Buy |
| 2020-07-27 | 개시 | SVB Leerink | Outperform |
| 2020-07-24 | 개시 | Jefferies | Buy |
모두보기
Immatics N V 주식(IMTX)의 최신 뉴스
Immatics NV (IMTXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immatics Shareholders Approve All Proposals at June 18, 2026 AGM - TipRanks
Immatics (IMTX) director Adam Leo Stone receives 48,000 stock options award - Stock Titan
Immatics (IMTX) awards director Alise Reicin 48,000 stock options - Stock Titan
Immatics (IMTX) director receives grant of 48,000 stock options at $9.09 - Stock Titan
Immatics (IMTX) director receives 48,000 stock options vesting in 2026 - Stock Titan
Immatics N.V. (IMTX) grants director options on 48,000 ordinary shares - Stock Titan
Immatics (IMTX) director Heather Mason receives 48,000 stock options at $9.09 strike - Stock Titan
48,000 Immatics (IMTX) options tied to board role granted - Stock Titan
Immatics (IMTX) director Mathias Hothum awarded 48,000 options at $9.09 strike - Stock Titan
Immatics N.V. (IMTX) 2026 AGM sees all voting items approved and strong turnout - Stock Titan
Immatics NV (IMTXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immatics NV (IMTXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immatics NV (IMTXW) Institutional Confidence - TradingKey
Immatics NV (IMTXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immatics NV (IMTXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immatics NV (IMTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immatics NV (IMTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immatics NV (IMTX) Institutional Confidence - TradingKey
Immatics NV (IMTXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immatics NV (IMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immatics NV (IMTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immatics NV (IMTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immatics NV (IMTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immatics NV (IMTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immatics: PRAME Is Becoming More Than A Single-Asset Story (NASDAQ:IMTX) - Seeking Alpha
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
How Investors May Respond To Immatics (IMTX) Advancing Its PRAME Franchise With New ASCO 2026 Data - Sahm
TD Cowen initiates coverage of Immatics NV (IMTX) with buy recommendation - MSN
The Technical Signals Behind (IMTX) That Institutions Follow - Stock Traders Daily
IMTX SEC FilingsImmatics N.V 10-K, 10-Q, 8-K Forms - Stock Titan
Immatics NV Stock Hits Day Low of $9.81 Amid Price Pressure - MarketsMojo
Immatics (IMTX) Faces Headwinds as Shares Decline 3.83% Amid Sector RotationStock News - newsline.com
Immatics N.V. (IMTX) Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Clinical InvestmentNegative Surprise Momentum - newsline.com
Immatics schedules annual general meeting for June 18 in Amsterdam By Investing.com - Investing.com India
Immatics Calls 2026 Annual General Meeting, Sets Record Date and Details New Incentive Plan - TipRanks
Immatics schedules annual general meeting for June 18 in Amsterdam - Investing.com
Immatics (IMTX) schedules 2026 AGM with vote on new stock plan - Stock Titan
IMTX Q1 2026 Earnings: Wider-than-Expected Loss Highlights Development-Stage ChallengesEPS Consistency Score - newsline.com
Immatics NV stock (NL0015255052): ASCO data spotlight PRAME cell therapy as Nasdaq shares hover arou - AD HOC NEWS
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting - Investing News Network
Immatics Showcases Strong Phase 1 Data for PRAME and MAGEA4/8 TCR Programs at ASCO 2026 - TipRanks
Immatics (NASDAQ: IMTX) shows promising PRAME and MAGEA4/8 trial results at ASCO 2026 - Stock Titan
Immatics Presents Clinical Activity and Response Dynamics - GlobeNewswire
Immatics N.V. Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing R&D Investment - The Legal Advocate
Immatics NV stock (NL0015255052): ASCO 2026 data on IMA401 and IMA203CD8 put TCR pipeline in focus - AD HOC NEWS
Immatics (IMTX) Shares Promising Phase 1 Results for IMA203CD8 T - GuruFocus
Immatics (IMTX) Unveils Promising Results from Phase 1 Trial of IMA401 - GuruFocus
Immatics (IMTX) Shares Promising Phase 1 Results for IMA203CD8 Therapy - GuruFocus
Immatics announces updated Phase 1 data for its Prame TCR T-cell therapy - TipRanks
Immatics N V (IMTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):